Tresiba and the combination drug Ryzodeg finally got the long-awaited approval from the FDA on 25 September, after being rejected in 2013 and directed to conduct a detailed study on cardiovascular outcomes. The approval has been based on the interim data of that study (called DEVOTE), which is expected to completed by 2016; Tresiba’s launch has been planned for Q1 16. Its approval was critical for the combination treatments, Ryzodeg (a combination with NovoRapid) and Xultophy (combinati
01 Oct 2015
Tresiba gets a green signal in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tresiba gets a green signal in the US
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
01 Oct 2015 -
Author:
Kamla Singh -
Pages:
2
Tresiba and the combination drug Ryzodeg finally got the long-awaited approval from the FDA on 25 September, after being rejected in 2013 and directed to conduct a detailed study on cardiovascular outcomes. The approval has been based on the interim data of that study (called DEVOTE), which is expected to completed by 2016; Tresiba’s launch has been planned for Q1 16. Its approval was critical for the combination treatments, Ryzodeg (a combination with NovoRapid) and Xultophy (combinati